Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities. www.selcia.com
- 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)
- GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance
- Stable Labelling (13C, 2H, 15N) Internal Standards, Metabolites and Impurities
- GLP Analysis Certification and Problem Solving including GLP NMR
Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration
Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway. Everything we do is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facilities in Nottingham and Alderley Park, UK housing over 500 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.